Definium's LSD-based drug cuts anxiety scores in second late-stage trial

Definium Therapeutics announced that its experimental LSD-based medication, designated DT120, achieved a statistically meaningful reduction in anxiety during a second late-stage, 12-week trial. Participants administered a 100-microgram dose experienced a 9.8-point decline on the Hamilton Anxiety Rating Scale, while the placebo group improved by 4.7 points, yielding a 5.1-point differential comparable to the company’s prior study.

This magnitude of effect is larger than that reported for many existing anxiety treatments, though cross-study comparisons remain challenging. The trial also revealed that some patients reported noticeable symptom relief by the second day after dosing, underscoring the rapid action of psychedelic-based approaches. Traditional options such as antidepressants typically require several weeks to become effective. The results position Definium to pursue regulatory approval as one of the first psychedelic drugs aimed at anxiety disorders.